{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T10:45:38Z","timestamp":1790333138147,"version":"4.1.0"},"reference-count":43,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2009,11,18]],"date-time":"2009-11-18T00:00:00Z","timestamp":1258502400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intl Journal of Cancer"],"published-print":{"date-parts":[[2010,7,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Osteosarcoma (OS) is the most common primary malignant tumor of bone in children and adolescents. In spite of successful control of the primary tumor, death from lung metastasis occurs in more than a third of patients. To investigate the efficacy of zoledronic acid (ZOL) on the development, progression and metastatic spread of OS, we used a rat model of OS, with features of the disease similar to human patients, including spontaneous metastasis to lungs. Rat OS cells were inoculated into the tibial marrow cavity of syngeneic rats. OS development was associated with osteolysis mixed with new bone formation, adjacent to the periosteum and extended into the surrounding soft tissue. Metastatic foci in the lungs formed 3\u20134 weeks postcancer cell transplantation. Treatment with a clinically relevant dose of ZOL was initiated 1 week after tumors were established and continued once weekly or as a single dose. ZOL preserved the integrity of both trabecular and cortical bone and reduced tumor\u2010induced bone formation. However, the overall tumor burden at the primary site was not reduced because of the persistent growth of cancer cells in the extramedullary space, which was not affected by ZOL treatment. ZOL treatment failed to prevent the metastatic spread of OS to the lungs. These findings suggest that ZOL as a single agent protects against OS\u2010induced bone destruction but lacks efficacy against pulmonary metastases in this rat model. ZOL may have potential value as an adjuvant therapy in patients with established OS.<\/jats:p>","DOI":"10.1002\/ijc.25051","type":"journal-article","created":{"date-parts":[[2009,11,19]],"date-time":"2009-11-19T00:15:04Z","timestamp":1258589704000},"page":"345-354","source":"Crossref","is-referenced-by-count":28,"title":["Zoledronic acid protects against osteosarcoma\u2010induced bone destruction but lacks efficacy against pulmonary metastases in a syngeneic rat model"],"prefix":"10.1002","volume":"127","author":[{"given":"Agatha","family":"Labrinidis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelley","family":"Hay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasilios","family":"Liapis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Findlay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Evdokiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,2]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-7091-3846-5","volume-title":"Bone and soft tissue tumors","author":"Campanacci M","year":"1999"},{"key":"e_1_2_6_3_2","first-page":"168","volume-title":"Pathology of bone and joint neoplasmsed","author":"Pringle JAS","year":"1999"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-2-6"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/89.22.1706"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0b013e328122d73f"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-008-0054-3"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/00003086-199109000-00003"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2006.05.005"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1080\/17453674.1997.11744716"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc867"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1615\/CritRevEukarGeneExpr.v10.i2.50"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8 <1581::AID-CNCR8>3.0.CO;2-N"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20000615)88:12 <2903::AID-CNCR4>3.0.CO;2-G"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20000615)88:12 <3054::AID-CNCR23>3.0.CO;2-Z"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.bi.65.070196.001325"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02983531"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1186\/bcr412"},{"key":"e_1_2_6_19_2","first-page":"2602","article-title":"Bisphosphonate treatment inhibits the growth of prostate cancer cells","volume":"61","author":"Lee MV","year":"2001","journal-title":"Cancer Res"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2006.10.004"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S8756-3282(03)00223-0"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1290\/1543-706X(2004)040<0113:TEOTBA>2.0.CO;2"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/jor.20129"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-1616"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2007.10.006"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.9-90004-3"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2008.02.004"},{"key":"e_1_2_6_28_2","first-page":"295","article-title":"Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer","volume":"9","author":"Corey E","year":"2003","journal-title":"Clin Cancer Res"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.14.3434"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00508-006-0644-8"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2005.02.020"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21530"},{"key":"e_1_2_6_33_2","first-page":"241","article-title":"Comparison of osteoblastic markers of nine clonal cell lines from rat osteosarcoma cells","volume":"9","author":"Takahashi K","year":"1991","journal-title":"J Bone Miner Metab"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djk054"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.20019"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-200106000-00007"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2008.09.026"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-07-0546"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2008.10.047"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.173.11.6767"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.2.384"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1385\/IR:26:1-3:207"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.20987"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-12-3665"}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fijc.25051","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.25051","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T06:57:52Z","timestamp":1697525872000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.25051"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,7,15]]}},"alternative-id":["10.1002\/ijc.25051"],"URL":"https:\/\/doi.org\/10.1002\/ijc.25051","archive":["Portico"],"relation":{},"ISSN":["0020-7136","1097-0215"],"issn-type":[{"value":"0020-7136","type":"print"},{"value":"1097-0215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,2]]}}}